Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors
03 April 2024
Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors...
READ MORE
Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for Pancreatic cancer and Acute Myeloid Leukemia (AML)
03 May 2022
Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001...
READ MORE
Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19
03 May 2022
Vopec Pharmaceuticals has received the NOC (no objection certificate) and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19....
READ MORE